Literature DB >> 30739161

IgG Fc Receptors: Evolutionary Considerations.

Stylianos Bournazos1.   

Abstract

Immunoglobulins (Ig), a critical component of the adaptive immune system, are present in all jawed vertebrates and through sophisticated diversification mechanisms are able to recognize antigens of almost infinite diversity. During mammalian evolution, IgG has emerged as the predominant Ig isotype that is elicited upon antigenic challenge, representing the most abundant isotype present in circulation. Along with the IgG molecule, a family of specialized receptors has evolved in mammalian species that specifically recognize the Fc domain of IgG. These receptors, termed Fcγ receptors (FcγRs), are expressed on the surface of effector leukocytes and upon crosslinking by the IgG Fc domain mediate diverse immunomodulatory processes with profound impact on several aspects of innate and adaptive immunity. FcγRs share a high degree of sequence homology among mammalian species and the ancestral locus, where the genes that encode for FcγRs are mapped, can be traced back early in mammalian evolution. FcγRs also share a number of common structural and functional properties among mammalian species and utilize highly conserved motifs for transducing signals upon engagement. Despite the high homology of FcγRs in diverse mammalian species, human FcγRs exhibit unique features relating to the gene organization, expression pattern in the various leukocyte populations, as well as affinity for human IgGs. Such inter-species differences in FcγRs biology between humans and other mammalian species represents a major limitation for the interpretation of in vivo studies on human IgG function using conventional animal models.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30739161     DOI: 10.1007/82_2019_149

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  9 in total

1.  Differential requirements for FcγR engagement by protective antibodies against Ebola virus.

Authors:  Stylianos Bournazos; David J DiLillo; Arthur J Goff; Pamela J Glass; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

Review 2.  Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects.

Authors:  Dhuha H Nawab
Journal:  Hum Vaccin Immunother       Date:  2021-11-29       Impact factor: 3.452

3.  Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy.

Authors:  Rachel Yamin; Andrew T Jones; Hans-Heinrich Hoffmann; Alexandra Schäfer; Kevin S Kao; Rebecca L Francis; Timothy P Sheahan; Ralph S Baric; Charles M Rice; Jeffrey V Ravetch; Stylianos Bournazos
Journal:  Nature       Date:  2021-09-21       Impact factor: 69.504

Review 4.  New Targets for Antiviral Therapy: Inhibitory Receptors and Immune Checkpoints on Myeloid Cells.

Authors:  Yanni Liu; Paul Nicklin; Yuan He
Journal:  Viruses       Date:  2022-05-25       Impact factor: 5.818

Review 5.  The Role of Antibodies in the Treatment of SARS-CoV-2 Virus Infection, and Evaluating Their Contribution to Antibody-Dependent Enhancement of Infection.

Authors:  Mohammed A H Farouq; Reinaldo Acevedo; Valerie A Ferro; Paul A Mulheran; Mohammed M Al Qaraghuli
Journal:  Int J Mol Sci       Date:  2022-05-28       Impact factor: 6.208

Review 6.  Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer.

Authors:  Tae Hyun Kang; Sang Taek Jung
Journal:  Biomolecules       Date:  2020-03-01

7.  Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection.

Authors:  Stylianos Bournazos; Davide Corti; Herbert W Virgin; Jeffrey V Ravetch
Journal:  Nature       Date:  2020-10-08       Impact factor: 49.962

8.  Sex effect on the correlation of immunoglobulin G glycosylation with rheumatoid arthritis disease activity.

Authors:  Altan Ercan
Journal:  Turk J Biol       Date:  2020-12-14

9.  Fc-engineered antibody therapeutics with improved efficacy against COVID-19.

Authors:  Rachel Yamin; Andrew T Jones; Jeffrey V Ravetch; Stylianos Bournazos; Hans-Heinrich Hoffmann; Kevin S Kao; Rebecca L Francis; Timothy P Sheahan; Ralph S Baric; Charles M Rice
Journal:  Res Sq       Date:  2021-05-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.